Cardiovascular (CV) events in patients with cancer can be caused by concomitant CV risk factors, cancer itself, and anticancer therapy. Since malignancy can dysregulate the hemostatic system, predisposing cancer patients to both thrombosis and hemorrhage, the administration of dual antiplatelet therapy (DAPT) to patients with cancer who suffer from acute coronary syndrome (ACS) or undergo percutaneous coronary intervention (PCI) is a clinical challenge to cardiologists. Apart from PCI and ACS, other structural interventions, such as TAVR, PFO-ASD closure, and LAA occlusion, and non-cardiac diseases, such as PAD and CVAs, may require DAPT. The aim of the present review is to review the current literature on the optimal antiplatelet therapy and duration of DAPT for oncologic patients, in order to reduce both the ischemic and bleeding risk in this high-risk population.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144375PMC
http://dx.doi.org/10.3390/jcdd10040135DOI Listing

Publication Analysis

Top Keywords

antiplatelet therapy
12
dual antiplatelet
8
ischemic bleeding
8
bleeding risk
8
patients cancer
8
cancer
5
therapy
4
therapy cancer
4
cancer balancing
4
balancing ischemic
4

Similar Publications

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Central University of Punjab, Bathinda, Punjab, India.

Background: Neuroinflammation has gained substantial attention for its involvement in the progression of Alzheimer's disease (AD).

Method: Recently, it was discovered that platelets, which make up 90% of the circulatory Aβ, encourage the development of AD. Therefore, we hypothesized to use a novel coumarin derivative PS21HKR, which is believed to possess anti-platelet and anti-inflammatory properties for the treatment of AD.

View Article and Find Full Text PDF

The popliteal artery segment is particularly challenging for endovascular treatment. Stents used for treating popliteal artery lesions are usually associated with an increased risk of stent fracture and re-occlusion. The Supera stent is designed to withstand mechanical stress, with a low risk of fracture.

View Article and Find Full Text PDF

Ischemic stroke is a significant global health problem associated with mortality and disability. Intracranial atherosclerotic stenosis (ICAS) is a leading cause of stroke and contributes to recurrent stroke, especially in Asian population. Because of the different pathophysiology and mechanisms of ICAS resulting in ischemic stroke compared to extracranial atherosclerotic stenosis (ECAS), treatment strategies for secondary prevention would be different.

View Article and Find Full Text PDF

The prevention of hepatic artery thrombosis (HAT) is pivotal for graft survival immediately after liver transplantation (LT). This study aimed to identify risk factors (RF) for early HAT (eHAT) and assess the benefit of antiplatelet prophylaxis (AP). This retrospective single-center study included 836 adult patients who underwent LT between 2007 and 2022.

View Article and Find Full Text PDF

Trends and cost structure of drug-based secondary prevention of ischemic strokes.

Neurol Res Pract

January 2025

Goethe University Frankfurt, University Hospital, Department of Neurology, Schleusenweg 2-16, 60528, Frankfurt am Main, Germany.

Background: Advances in secondary stroke prevention, including direct oral anticoagulants (DOACs), dual antiplatelet therapies (DAPT), and cardiovascular risk management, have changed costs over the past decade. This study aimed to evaluate annual treatment costs and trends in drug-based secondary prophylaxis after ischemic strokes.

Methods: Annual treatment costs were evaluated using the net costs per defined daily dosage (DDD) of discharge medications for ischemic stroke patients treated in 2020 at the University Hospital Frankfurt, Germany.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!